Discover 3,075 paid clinical trials in Houston, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Houston is home to world-renowned medical centers offering a variety of trials targeting conditions such as cancer, heart disease, diabetes, and Alzheimer’s. Healthy volunteers interested in paid research opportunities, as well as individuals in need of trials for specific conditions, can participate in these studies to access cutting-edge treatments and contribute to the development of innovative therapies.
Filter
2
Filter results
Results: 3,075
Active & Responsive
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
for
End Stage Renal Disease (ESRD), Kidney Failure,
Location: Houston TX, Tampa FL, Sarasota FL, Louisville KY,
Sponsor: W.L.Gore & Associates
Sex: All
Age: 18 - 70+
Code: NCT04671771
Recruiting
Active & Responsive
Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity
for
Endoscopic Sleeve Gastroplasty, Obesity
Location: Houston TX, Sugar Land TX
Sponsor: The Methodist Hospital Research Institute
Sex: All
Age: 18+
Code: NCT06339320
Recruiting
Active & Responsive
Sentinel Node Biopsy in Endometrial Cancer
for
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
Location: Houston TX
Sponsor: Queensland Centre for Gynaecological Cancer
Sex: Female
Age: 18+
Code: NCT04073706
Phase3, Recruiting
Active & Responsive
Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
for
End Stage Liver Disease
Location: Houston TX
Sponsor: LyGenesis, Inc.
Sex: All
Age: 18 - 70
Code: NCT04496479
Phase2, Recruiting
Active & Responsive
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
for
Breast Neoplasms, Breast Cancer
Location: Houston TX, Dallas TX, Nashville TN, Skokie IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06797635
Phase2, Recruiting
Active & Responsive
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)